ClinicalTrials.gg
RecruitingNCT07594626Updated Aug 25, 2026

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

A Phase 1/2 interventional study of Biospecimen Collection and Computed Tomography in Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma and Metastatic Esophageal Carcinoma, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Northwestern University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colonic Neoplasms by Northwestern University — 2 open to participants now, 2 under way, none of them phase 3. Colonic Neoplasms · Northwestern University.

Started
2026
the only one that year
Phase 1/2
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Colonic Neoplasms by Northwestern University, this one is the only one that started in 2026, is one of 3 in phase 1/2, and was the 10th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

2 of the 10 studies in Colonic Neoplasms by Northwestern University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colonic Neoplasms by Northwestern University, or all of them as a file.
02

Study summary

This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the body (metastatic). The MTAP gene helps cells recycle important parts needed to make deoxyribonucleic acid (DNA), which is needed for cell growth and function. MTAP deletion means that the MTAP gene is missing. BMS-986504, a PRMT5 inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Giving BMS-986504 in combination with pemetrexed may be safe, tolerable, and/or effective in treating patients with metastatic solid tumors with MTAP deletion.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the safety, tolerability and dose limiting toxicity (DLT) of PRMT5 inhibitor BMS-986504 (BMS-986504) in patients with metastatic solid tumors with homozygous deletion of the MTAP gene treated with BMS-986504 in combination with pemetrexed.

SECONDARY OBJECTIVES:

I. To assess the overall response rate (ORR) in patients with metastatic solid tumors homozygous deletion of the MTAP gene treated with BMS-986504 in combination with pemetrexed.

II. To assess the duration of response (DOR) among patients achieving an objective response, defined as the time from first documented response to disease progression or death.

EXPLORATORY OBJECTIVES:

I. To descriptively summarize overall survival (OS) in the treated population. II. To descriptively summarize progression-free survival (PFS) in the treated population.

III. To descriptively assess the pharmacokinetics of BMS-986504 in combination with pemetrexed.

OUTLINE:

Patients receive BMS-986504 orally (PO) once daily (QD) on days 1-21 and pemetrexed intravenously (IV) over 10 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and computed tomography (CT) throughout the study.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 12 months.

03

Conditions studied

  • Metastatic Biliary Tract Carcinoma
  • Metastatic Colon Carcinoma
  • Metastatic Esophageal Carcinoma
  • Metastatic Malignant Digestive System Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Pancreatic Carcinoma
  • Stage IV Colon Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COHORT A (INCLUDING SAFETY RUN IN, STAGE I AND STAGE II) AND COHORT B:
  • Patients must have or cytologically confirmed solid tumor of gastrointestinal origin with MTAP deletion including pancreatic cancer, biliary cancer, esophageal cancer and colon cancer (Cohort A) or other metastatic solid with MTAP deletion (Cohort B) confirmed by validated next generation sequencing tissue techniques only

    • NOTE: Both internal and external validated next generation sequencing (NGS) panels are acceptable
  • Progressive disease (PD) after one previous standard of care

    • NOTE: symptoms from clinical evaluation for PD will be sufficient
  • Patients must have at least 1 per (RECIST) version (v) 1.1, measured preferably by computed tomography (CT) scan

    • Note: Tumor lesions in a previously irradiated area are not considered measurable unless they show unequivocal progression
    • NOTE: There is no limit on previous treatment lines
  • Patients who have received any or systemic chemotherapy are eligible

    • Note: treatment cannot have included prior pemetrexed unless in the case of non-small cell lung cancer (NSCLC) cancer type. Any prior intravesical therapy, or immunotherapy is allowed. At least 3 weeks (21 days) from treatment since prior chemotherapy or radiation therapy or targeted agent is required
  • Patients must be aged ≥ 18 years
  • Patients must exhibit an (ECOG) performance status of 0-1
  • (ANC) ≥ 1,500/mcL (growth factor allowed and can be added at the discretion of the treating oncologist

    • Growth factors are excluded from being used during the DLT observation period (cycle 1) unless they are being used to treat a grade 4 adverse event which will be counted as a DLT. If growth factors are being used for grade ≤ 3 toxicity, then patients will not be evaluable for DLT assessment
  • (Hgb) ≥ 8.5 g/dL (without the need for transfusion within the previous one week)
  • (PLT) ≥ 100,000/mL (without the need for platelet transfusion within the previous one week)
  • Total ≤ 1.5 x Institutional (ULN), except subjects with Gilbert's syndrome or liver metastases, who must have a baseline total bilirubin ≤ 3.0 mg/dL
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present
  • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present
  • ≥ 60 mL/min/1.73 m\^2 using the standard Cockcroft and Gault formula
  • Patients must have the ability to comply with folic acid, vitamin B12 and as directed by study team and as per standard of care for pemetrexed use
  • Patients with treated are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Pemetrexed is known to be teratogenic. Reproductive toxicology studies with MRTX1719 have not been performed. The investigator or designee shall counsel patients of (POCBP) participants and male (as assigned at birth) participants who are sexually active with POCBP on the importance of pregnancy prevention, the implications of an unexpected pregnancy, and the potential of fetal toxicity occurring due to transmission of study intervention present in seminal fluid to a developing fetus, even if the participant has undergone a successful vasectomy or if the partner is pregnant. If needed, participants should be advised to seek advice about egg or sperm donation and cryopreservation of germ cells before treatment

    • Patients of childbearing potential POCBP

      • A POCBP is any patient with an egg-producing reproductive tract who meets the following criteria:

        • Has not undergone a hysterectomy or bilateral oophorectomy
        • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally for > 12 months)
      • POCBP are not permitted to use hormonal methods alone as a highly effective method of contraception and must use an additional non-hormonal highly effective method of contraception. POCBP must agree to use a combination of a hormonal and a non-hormonal contraceptive method or a non-hormonal method alone that is highly effective (with a failure rate of \< 1% per year) during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer
      • POCBP participants must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period
      • Male (as assigned at birth) participants will be required to always use a latex or other synthetic condom during any sexual activity (eg, vaginal, anal, oral) with POCBP, even if the participant has undergone a successful vasectomy or if the partner is pregnant or breastfeeding. Male (as assigned at birth) participants should continue to use a condom during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer
      • POCBP partners of male (as assigned at birth) participants should be advised to use a highly effective method of contraception during the intervention period and for at least 6 months after the last dose of study intervention for the male participant, or according to approved local product label requirements for pemetrexed, whichever is longer
      • Male (as assigned at birth) participants with a pregnant or breastfeeding partner must agree to remain abstinent from sexual activity or use a male condom during any sexual activity (eg, vaginal, anal, oral), even if the participant has undergone a successful vasectomy, during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer
      • Male (as assigned at birth) participants must refrain from donating sperm during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer
      • Breastfeeding partners of male (as assigned at birth) participants should be advised to consult their health care provider about using appropriate highly effective contraception during the time the male participant is required to use condoms
      • POCBP must have a negative pregnancy test prior to registration on study
  • The ability to interrupt nonsteroidal antiinflammatory drugs (NSAIDS) or aspirin at higher dose (> 1.3 g daily) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed

Exclusion criteria

Exclusion Criteria:

  • STAGE I AND II, COHORT A (INCLUDING SAFETY RUN IN) AND B:
  • Patients who received prior pemetrexed containing chemotherapy (apart from NSCLC)
  • Patients with prior treatment with a PRMT5 or MAT2A inhibitor therapy
  • Patients with pre-existing interstitial lung disease (ILD)
  • Patients who have had chemotherapy or radiotherapy ≤ 21 days prior to planned treatment start date.

    • Note: seven days or fewer of palliative radiotherapy for non-CNS disease, is permitted. No is required
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy per National Cancer Institute (NCI) (CTCAE) v 5.0
  • Patients who are receiving any other agents or devices. Patients start of study treatment will be based on their discontinuation and recovery from clinically significant adverse events from their most recent therapy or intervention prior to study enrollment
  • Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed
  • Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:

    • Ongoing or active infection requiring systemic treatment
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
  • Patients with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification

    • Note: To be eligible for this trial, patients should be class 2B or better
  • Patients with presence of third space fluid which cannot be controlled by drainage

    • Note: For patients who develop or have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before or during initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing. However, if, in the investigator's opinion, the effusion represents progression of disease, the patient should be discontinued from study therapy
  • Patients who are not able to understand and voluntarily sign a written and is not willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures
  • Patients who are pregnant or nursing
  • Patients with history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications
  • Patients with Fridericia's formula- interval (QTcF) prolongation > 480 msec, except for right bundle branch block, per the investigator's assessment
  • Patients with ongoing need for a medication with a known risk of Torsade's de Pointes that cannot be switched to an alternative treatment prior to study entry
  • Patients with ongoing need for a medication known as a strong inhibitor or strong inducer of cytochrome P450 3A4 () and/or P-glycoprotein (P-gp) or a proton-pump inhibitor and potassium-competitive acid blockers that cannot be switched to an alternative treatment prior to study entry

    • NOTE: The following drug interaction databases and other literature can be utilized to determine the CYP3A4/P-gp inhibitors and inducers
    • Note: Please consult with the manufacturer for any uncertainties regarding potential CYP3A4 and P-gp modulators
  • Patients with inability to comply with restrictions and prohibited treatments
  • Patients taking any botanical preparation (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study within 4 weeks prior to treatment. The concurrent use of any botanical preparation is not permitted while on study
  • Patients with a known history of (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration. Please note this lab is not a requirement for eligibility, however, if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients with a known history of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Please note this lab is not a requirement for eligibility; however if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients with a known history of virus (HCV) infection must have been treated and cured. For patients with a known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Please note this lab is not a requirement for eligibility; however if it has been completed previously as part of the patient's health care, it should be documented for eligibility
  • Patients who take live/attenuated vaccine received within 30 days of first treatment. The use of inactivated seasonal influenza vaccines (e.g., Fluzone®) will be permitted on study without restriction
  • Patient has not received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug:

    • Surgery with general anesthesia - within 7 days of first dose of study drug
    • Surgery with local anesthesia - with 3 days of first dose of study drug
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Treatment (BMS-986504, pemetrexed)

    Patients receive BMS-986504 PO QD on days 1-21 and pemetrexed IV over 10 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and CT throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Pemetrexed · Drug: PRMT5 Inhibitor BMS-986504

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: MTA, Multitargeted Antifolate, Pemfexy

  • DrugNavlimetostatStudies of NavlimetostatNavlimetostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: BMS 986504, BMS-986504, BMS986504, MRTX 1719, MRTX-1719, MRTX1719, MTA-cooperative PRMT5 Inhibitor BMS-986504, MTA-cooperative PRMT5 Inhibitor MRTX1719, PRMT5-MTA Complex Inhibitor MRTX1719, PRMT5-MTA Inhibitor MRTX1719

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity

    Will be summarized descriptively by frequency and grade using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

    Time frame: Up to 21 days

  2. Incidence of treatment-emergent adverse events (AEs)

    Will be summarized descriptively by frequency and grade using the NCI CTCAE v 5.0. Will be tabulated by system organ class and preferred term.

    Time frame: Up to 30 days after last dose of study treatment

  3. Incidence of serious AEs

    Will be summarized descriptively by frequency and grade using the NCI CTCAE v 5.0.

    Time frame: Up to 30 days after last dose of study treatment

  4. Incidence of grade 3 or greater adverse events

    Will be summarized descriptively by frequency and grade using the NCI CTCAE v 5.0.

    Time frame: Up to 30 days after last dose of study treatment

  5. Number of patients who discontinue treatment due to toxicity

    Time frame: Up to 30 days after last dose of study treatment

Secondary outcomes

  1. Objective response rate

    Will be measured according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Will be defined as the overall percentage of patients with complete response (CR) plus partial response (PR). Point estimates and corresponding two-sided 95% exact (Clopper-Pearson) confidence intervals will be reported. Will be compared against the null hypothesis rate of 15% using a one-sided binomial test consistent with the Simon's two-stage design framework.

    Time frame: From baseline until disease progression, initiation of subsequent anti-cancer therapy, or completes study participation, whichever occurs first, assessed up to 12 months

  2. Duration of response (DOR)

    Disease progression will be defined as experiencing progressive disease per RECIST v 1.1 or death due to disease. Will be analyzed using the Kaplan-Meier method, with censoring at the date of the last tumor assessment prior to progression or death. Median DOR and corresponding 95% confidence intervals will be reported.

    Time frame: From the day when CR or PR is first observed until the earlier of the day of first documented disease progression or death from any cause, assessed up to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.

Of 59 phase 1/2 interventional studies under Colonic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 93. This study's planned 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Dec 9, 2030
CompletionEst.
Dec 9, 2030
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07594626
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Aug 21, 2026
Primary completion
Dec 9, 2030 (estimated)
Completion
Dec 9, 2030 (estimated)
Last update
Aug 25, 2026

Study contacts

Study Coordinator
Contact
cancer@northwestern.edu
3126951301
Devalingam Mahalingam, MD, PhD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion